Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

<p>ABSTRACT</p> <p>Purpose</p> <p>Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its acceptance, despite significant durable relapse prevention...

Full description

Bibliographic Details
Main Authors: Fountzilas George, Panagiotou Petros, Markopoulos Christos, Stratigos Alexandros, Polyzos Aristidis, Tsoutsos Dimosthenis, Pectasides Eirini, Buchbinder Elizabeth, Metaxas Yannis, Spyropoulou-Vlachou Maria, Koon Henry, Dafni Urania, Gogas Helen, Castana Ourania, Skarlos Pantelis, Atkins Michael B, Kirkwood John M
Format: Article
Language:English
Published: BMC 2010-11-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/8/1/108

Internet

http://www.translational-medicine.com/content/8/1/108

Similar Items